We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

HemoControl System Activated in Hemodiafiltration Treatments (SOCRATHE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01582867
Recruitment Status : Completed
First Posted : April 23, 2012
Last Update Posted : April 20, 2017
Sponsor:
Collaborator:
Information provided by (Responsible Party):

Study Description
Brief Summary:
The current study aims to assess the HemoControl prescription in On-Line Hemodiafiltration treatment.

Condition or disease Intervention/treatment
Renal Failure Device: ARTIS hemodialysis system

Detailed Description:

Hemodiafiltration (HDF) is a dialysis technique that allows the removal of high molecular weight toxic solutes exploiting the convective transport through the dialyzer membrane: at the same time, the HDF has a positive impact on the systemic hemodynamic, ameliorating in this way the tolerance of the treatment. Unfortunately, also the HDF therapy can be not well tolerated, introducing in the patients serious hypovolemia during the removal of the body water accumulated in the interdialytic period.

The HemoControl system, automatically controlling the relative blood volume change of the patient, avoids the onset of the hypovolemia. Today the HemoControl system can be used only during conventional hemodialysis treatments; the objective of this study is to combine the advantages of the intradialytic hemodynamic stabilization achievable by means of HemoControl with the inherent advantages, both of depurative and cardiovascular kind, typical of the Hemodiafiltration technique.


Study Design

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 7 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Studio Cross-Over Controllato Randomizzato Sul Dispositivo ArTis Con Hemocontrol in Emodiafiltrazione - SOCRATHE
Study Start Date : May 2012
Primary Completion Date : May 2013
Study Completion Date : May 2013

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Dialysis
U.S. FDA Resources

Arms and Interventions

Arm Intervention/treatment
Experimental: HD and HDF
During one part of the study (study phase A) patients will undergo hemodialysis (HD) treatments with Hemoscan over 2 weeks (Run-In period), followed by 12 HD sessions with HemoControl during the following 4 to 6 weeks. Separated by a one week wash out period, the same patients will be switched to On-Line Hemodiafiltration (HDF) treatments (study phase B), for a Run-In period of 2 weeks with Hemoscan, followed by 12 On-Line HDF sessions with HemoControl over the last 4 to 6 weeks of the study period.
Device: ARTIS hemodialysis system

Software versions:

Control Product: 8.06.01KA. Study Product: 8.06.01B_HC01

Other Names:
  • Artis™ hemodialysis system
  • HEMOCONTROL™
  • GAMBRO
Experimental: HDF and HD
patients will be treated vice versa, starting with On-Line Hemodiafiltration (HDF) followed by hemodialysis (HD) with the same respective Run-In periods and a washout period as patients in Arm hemodialysis (HD) and Hemodiafiltration (HDF) .
Device: ARTIS hemodialysis system

Software versions:

Control Product: 8.06.01KA. Study Product: 8.06.01B_HC01

Other Names:
  • Artis™ hemodialysis system
  • HEMOCONTROL™
  • GAMBRO


Outcome Measures

Primary Outcome Measures :
  1. Sodium mass balance [ Time Frame: during dialysis treatment within 18 weeks ]
    • to determine whether the same HemoControl prescription is usable in On-Line Hemodiafiltration (HDF) and hemodialysis (HD) treatments and, if not,
    • to assess the existence of a proper HemoControl prescription in On-Line Hemodiafiltration (HDF) treatment.


Secondary Outcome Measures :
  1. blood pressure [ Time Frame: Pre-dialytic within 18 weeks ]
    difference between the pre-treatment systolic and diastolic blood pressures in On-Line Hemodiafiltration (HDF) and hemodialysis (HD) with respect to the control treatments

  2. thirst perception [ Time Frame: during dialysis within 18 weeks ]
    Average difference between the thirst score reported by the patient during On-Line Hemodiafiltration (HDF) and hemodialysis (HD) treatments with respect to the score reported during the control treatments

  3. weight gain [ Time Frame: between dialysis treatments within 18 weeks ]
    difference between the interdialytic weight gain in On-Line Hemodiafiltration (HDF) and hemodialysis (HD) treatments with respect to the control treatment


Eligibility Criteria

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • A subject must meet ALL of the following inclusion criteria in order to participate in this study:

    • ESRD in chronic dialysis treatments for at least 3 months
    • Age ≥ 18 years
    • Body weight ≥ 40 kg
    • Blood flow rate ≥ 250 ml/min with a recirculation of the vascular access < 5%
    • Use of not fractioned heparin in continuous infusion as anticoagulant
    • Stable anticoagulation dosage over the last 6 treatments
    • Stable dialysis prescription (Qb, Qd, treatment time) over the last 6 treatments
    • Informed consent for participating to the study
    • Stable Haemoglobin concentration at beginning of the treatment lower than or equal to 14 g/dl.

Exclusion Criteria:

  • A subject shall NOT participate in the study if he/she meets ANY of the following criteria:

    • HIV positivity
    • Active Hepatitis A, B or C
    • Pregnancy
    • Participating in other clinical investigations during the course of this study
    • Failed to release consent
    • Known coagulation disorders (clotting problems)
    • Known bleeding risk
    • Clinical or laboratory diagnosis of acute infection
    • Recent (last 4 weeks) surgical intervention
    • Therapy prescribed is only HD, HF or isolated UF mode
    • Active phase cancer,
    • Active phase immune disease.
    • Serious hemostasis disorders.
Contacts and Locations

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01582867


Locations
Italy
Policlinico Sant'Orsola Malpighi
Bologna, (bo), Italy, 40138
Sponsors and Collaborators
Baxter Healthcare Corporation
Gambro Dasco S.p.A.
Investigators
Principal Investigator: Antonio Santoro, Dr. POLICLINICO SANT'ORSOLA MALPIGHI
More Information

Responsible Party: Baxter Healthcare Corporation
ClinicalTrials.gov Identifier: NCT01582867     History of Changes
Other Study ID Numbers: 1495
First Posted: April 23, 2012    Key Record Dates
Last Update Posted: April 20, 2017
Last Verified: March 2017

Keywords provided by Baxter Healthcare Corporation:
Hemodiafiltration
Hemodialysis
Sodium
Artis
renal failure

Additional relevant MeSH terms:
Renal Insufficiency
Kidney Diseases
Urologic Diseases